Atea completes C-BEYOND Phase 3 trial enrollment with 880 HCV patients.

Atea Pharmaceuticals has completed enrollment of over 880 treatment-naïve patients in the C-BEYOND Phase 3 trial comparing its fixed-dose combination of bemnifosbuvir and ruzasvir to the sofosbuvir and velpatasvir regimen for HCV treatment. Topline results are expected mid-2026. The company is also conducting the C-FORWARD Phase 3 trial, with enrollment completion expected mid-2026 and topline results anticipated year-end 2026. These trials are the first global head-to-head trials of direct-acting antivirals for HCV treatment.